Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: A randomized controlled trial

Neurology

Volumn 84, Issue 23, 2015, Pages 2338-2346

  Van Den Elsen, Geke A H ^a   Ahmed, Amir I A ^a,b,d   Verkes, Robbert Jan ^b   Kramers, Cees ^b,e   Feuth, Ton ^c   Rosenberg, Paul B ^f   Van Der Marck, Marjolein A ^a   Olde Rikkert, Marcel G M ^a  

^a Departments of Geriatric Medicine Radboudumc Alzheimer Centre   (United States)

^b Department of Pharmacology and Toxicology ^*  (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d VINCENT VAN GOGH INSTITUTE FOR PSYCHIATRY   (Netherlands)

^e CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; LIVER ENZYME; PLACEBO; TETRAHYDROCANNABINOL; CANNABINOID RECEPTOR AGONIST; DRONABINOL;

AGED; AGITATION; ALZHEIMER DISEASE; APHASIA; ARTICLE; BACKACHE; BALANCE DISORDER; BARTHEL INDEX; BEHAVIOR DISORDER; BRADYKINESIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COGNITIVE DEFECT; COHEN MANSFIELD AGITATION INVENTORY; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DECREASED APPETITE; DELIRIUM; DEMENTIA; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; FAINTNESS; FATIGUE; FEMALE; GASTROESOPHAGEAL REFLUX; HEADACHE; HUMAN; INTENTION TO TREAT ANALYSIS; INTERTRIGO; INTRAOCULAR HEMORRHAGE; LIMB PAIN; MALAISE; MALE; MIOSIS; MULTICENTER STUDY; MUSCLE SPASM; MUSCLE WEAKNESS; NAUSEA; NECK PAIN; NEPHROTOXICITY; NEUROPSYCHIATRY INVENTORY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRESYNCOPE; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; RHINOPHARYNGITIS; SENSORY DYSFUNCTION; SIDE EFFECT; SKIN DISEASE; SOMNOLENCE; SYMPTOMATOLOGY; THORAX PAIN; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; URGE INCONTINENCE; AGGRESSION; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; PSYCHOMOTOR AGITATION; VERY ELDERLY;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; AGGRESSION; CANNABINOID RECEPTOR AGONISTS; DEMENTIA; DOUBLE-BLIND METHOD; DRONABINOL; HUMANS; MALE; PSYCHOMOTOR AGITATION; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84930690820     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001675     Document Type: Article

References (40)

1. Steinberg M, Shao H, Zandi P, et al. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry 2008;23:170-177.
2. Livingston G, Kelly L, Lewis-Holmes E, et al. A systematic review of the clinical effectiveness and cost-effectiveness of sensory, psychological and behavioural interventions for managing agitation in older adults with dementia. Health Technol Assess 2014;18:1-226, v-vi.
3. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: metaanalysis of randomized placebo-controlled trials. JAMA 2005;294:1934-1943.
4. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: metaanalysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006;14:191-210.
5. Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ 2005;330:445.
6. Gauthier S, Cummings J, Ballard C, et al. Management of behavioral problems in Alzheimer's disease. Int Psychogeriatr 2010;22:346-372.
7. Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 2002;288:1475-1483.
8. Zuidema SU, Derksen E, Verhey FR, Koopmans RT. Prevalence of neuropsychiatric symptoms in a large sample of Dutch nursing home patients with dementia. Int J Geriatr Psychiatry 2007;22:632-638.
9. Husebo BS, Ballard C, Sandvik R, Nilsen OB, Aarsland D. Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. BMJ 2011;343:d4065.
10. Koppel BS, Brust JC, Fife T, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2014;82:1556-1563.
11. Klumpers LE, Beumer TL, van Hasselt JG, et al. Novel Delta(9)-tetrahydrocannabinol formulation Namisol (R) has beneficial pharmacokinetics and promising pharmacodynamic effects. Br J Clin Pharmacol 2012; 74:42-53.
12. Walther S, Mahlberg R, Eichmann U, Kunz D. Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology 2006;185:524-528.
13. Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriatr Psychiatry 1997;12:913-919.
14. Baker D, Pryce G, Giovannoni G, Thompson AJ. The therapeutic potential of cannabis. Lancet Neurol 2003;2: 291-298.
15. Ramirez BG, Blazquez C, Gomez del Pulgar T, Guzman M, de Ceballos ML. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 2005; 25:1904-1913.
16. Aso E, Sanchez-Pla A, Vegas-Lozano E, Maldonado R, Ferrer I. Cannabis-based medicine reduces multiple pathological processes in AbetaPP/PS1 mice. J Alzheimers Dis 2015;43:977-991.
17. van den Elsen GA, Ahmed AI, Lammers M, et al. Efficacy and safety of medical cannabinoids in older subjects: a systematic review. Ageing Res Rev 2014;14:56-64.
18. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263-269.
19. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN International Workshop. Neurology 1993;43:250-260.
20. Achterberg WP, Pieper MJ, van Dalen-Kok AH, et al. Pain management in patients with dementia. Clin Interv Aging 2013;8:1471-1482.
21. Woodward MR, Harper DG, Stolyar A, Forester BP, Ellison JM. Dronabinol for the treatment of agitation and aggressive behavior in acutely hospitalized severely demented patients with noncognitive behavioral symptoms. Am J Geriatr Psychiatry 2014;22:415-419.
22. Scott NW, McPherson GC, Ramsay CR, Campbell MK. The method of minimization for allocation to clinical trials: a review. Control Clin Trials 2002;23:662-674.
23. Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 1997; 48:S10-S16.
24. Cohen-Mansfield J. Conceptualization of agitation: results based on the Cohen-Mansfield agitation inventory and the agitation behavior mapping instrument. Int Psychogeriatr 1996;8(suppl 3):309-315; discussion 351-354.
25. Sainsbury A, Seebass G, Bansal A, Young JB. Reliability of the Barthel Index when used with older people. Age Ageing 2005;34:228-232.
26. Thorgrimsen L, Selwood A, Spector A, et al. Whose quality of life is it anyway? The validity and reliability of the Quality of Life-Alzheimer's Disease (QoL-AD) scale. Alzheimer Dis Assoc Disord 2003;17:201-208.
27. Ahmed AI, van den Elsen GA, Colbers A, et al. Safety and pharmacokinetics of oral delta-9-tetrahydrocannabinol in healthy older subjects: a randomized controlled trial. Eur Neuropsychopharmacol 2014;24:1475-1482.
28. Wechsler D. Wechsler Memory Scale-Revised Manual. San Antonio, TX: Psychological Corporation; 1987.
29. Cummings JL. Neuropsychiatric Inventory (NPI): setting the standard for Alzheimer research. Available at: www. npitest.net.
30. Mega MS, Masterman DM, O'Connor SM, Barclay TR, Cummings JL. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol 1999;56:1388-1393.
31. Ihl R, Bachinskaya N, Korczyn AD, et al. Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial. Int J Geriatr Psychiatry 2011;26:1186-1194.
32. Reese JP, Hessmann P, Seeberg G, et al. Cost and care of patients with Alzheimer's disease: clinical predictors in German health care settings. J Alzheimers Dis 2011;27: 723-736.
33. Fox C, Crugel M, Maidment I, et al. Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial. PLoS One 2012;7: e35185.
34. Porsteinsson AP, Drye LT, Pollock BG, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA 2014;311:682-691.
35. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006;355:1525-1538.
36. McCarney R, Warner J, Iliffe S, van Haselen R, Griffin M, Fisher P. The Hawthorne Effect: a randomised, controlled trial. BMC Med Res Methodol 2007;7:30.
37. Walther S, Schupbach B, Seifritz E, Homan P, Strik W. Randomized, controlled crossover trial of dronabinol, 2.5 mg, for agitation in 2 patients with dementia. J Clin Psychopharmacol 2011;31:256-258.
38. Adler JN, Colbert JA. Clinical decisions: medicinal use of marijuana: polling results. N Engl J Med 2013;368:e30.
39. Farrell M, Buchbinder R, Hall W. Should doctors prescribe cannabinoids? BMJ 2014;348:g2737.
40. Kales HC, Gitlin LN, Lyketsos CG; Detroit Expert Panel on A, Management of Neuropsychiatric Symptoms of D. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel. J Am Geriatr Soc 2014;62:762-769.